Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

To describe the characteristics of patients with MS reporting cryptococcal meningitis (CM) while treated with fingolimod. The Novartis safety database was searched for cases with CM between January 26, 2006, and February 28, 2020. The reporting rate of CM was estimated based on the case reports received and exposure to fingolimod in the postmarketing setting during the relevant period. A total of 60 case reports of CM were identified, mostly from the United States. The median age was 48 years, and 51.8% were women. Most of the patients had recovered or were recovering at the time of final report. A fatal outcome occurred in 13 cases. During the study period, the rate of CM in patients with MS receiving fingolimod was estimated to be 8 per 100,000 patient-years (95% CI: 6.0; 10.0). The incidence of CM seemed to increase with duration of treatment; however, this relationship remains uncertain due to wide CIs and missing data. The causal relationship between fingolimod treatment and CM is not yet fully understood. The CM mortality rate in fingolimod-treated patients is similar to that reported in HIV-negative patients. Vigilance for signs and symptoms of CM in patients receiving fingolimod, particularly the new onset of headaches and altered mental status, is essential. Early diagnosis and treatment are critical to reducing CM-associated mortality. Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.


Maurizio Del Poeta, Brian J Ward, Benjamin Greenberg, Bernhard Hemmer, Bruce A C Cree, Sreelatha Komatireddy, Jitendriya Mishra, Roseanne Sullivan, Ajay Kilaru, Alan Moore, Thomas Hach, Joseph R Berger. Cryptococcal Meningitis Reported With Fingolimod Treatment: Case Series. Neurology(R) neuroimmunology & neuroinflammation. 2022 May;9(3)

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35318259

View Full Text